| Literature DB >> 25740916 |
Yi Zhang1, Yuting Wang1, Lei Wang1, Mei Bai1, Xiuwu Zhang1, Xiongzhao Zhu2.
Abstract
BACKGROUND: Early life stress has been demonstrated to increase the risk of developing depression in adulthood. However, the roles and associated molecular mechanisms of stresses in the onset and relapse of depression have yet to be fully elucidated.Entities:
Keywords: depression; dopamine receptor D2; microRNAs; stress
Mesh:
Substances:
Year: 2015 PMID: 25740916 PMCID: PMC4571637 DOI: 10.1093/ijnp/pyv025
Source DB: PubMed Journal: Int J Neuropsychopharmacol ISSN: 1461-1457 Impact factor: 5.176
Sequences for Primers or miRNAs
| Sequences | |
|---|---|
| Primer for Real time RT-PCR | |
| Rat | |
| miR-9 | Forward: 5’-TCTTTGGTTATCTAGCTGTATGA-3’ |
| miR-141 | Forward: 5’-TAACACTGTCTGGTAAAGATGG-3’ |
| miR-200a | Forward: 5’-TAACACTGTCTGGTAACGATGT-3’ |
| miR-326 | Forward: 5’-CAAACGCCCTTCCTCCAGTA-3’ |
| U6 | Forward: 5’-GCAAGGATGACACGCAAATTC-3’ |
| DRD2 | Forward: 5’-CTTGATAGTCAGCCTTGCTGTG-3’ |
| Reverse: 5’-AGGGCACGTAGAATGAGACAAT-3’ | |
| β-actin | Forward: 5’-GGAGATTACTGCCCTGGCTCCTA-3’ |
| Reverse: 5’-GACTCATCGTACTCCTGCTTGCTG-3’ | |
| Human | |
| miR-9 | Forward: 5’-CTCTTTGGTTATCTAGCTGTATGA-3’ |
| miR-326 | Forward: 5’-GGCCCTTCCTCCAGAAAAAA-3’ |
| U6 | Forward: 5’-GCTTCGGCAGCACATATACTAAAAT-3’ |
| DRD2 | Forward: 5’-CCAGAGATTCCCAAGCCAAA-3’ |
| Reverse: 5’-GGTAAGAGGGCAAAGGATGAG-3’ | |
| β-actin | Forward: 5’-GCGGAAGTATTCTGTTTGGATTG -3’ |
| Reverse: 5’-GAGGACCAGCCTCATCATATTC -3’ | |
| Primer for PCR (Human) | |
| DRD2 3’UTR WT | Forward: 5’-AATCTCGAGCTCTGCTGCCTGCCCGCAC-3’ |
| Reverse: 5’-GGAGCGGCCGCGAAGGTGACTCGTCAAAG-3’ | |
| DRD2 3’UTR MUT | Forward: 5’-CCTTGGCCAATGTTCTGCAGCCGCCTTCCTTGAC-3’ |
| Reverse: 5’-GGCTGCAGAACATTGGCCAAGGATAGGGGGACTG-3’ | |
| miRNAs Mimics | |
| NC | Sense: 5’-UUCUCCGAACGUGUCACGUTT-3’ |
| Antisense 5’-ACGUGACACGUUCGGAGAATT-3’ | |
| miR-9 | Sense: 5’- UCUUUGGUUAUCUAGCUGUAUGA-3’ |
| Antisense 5’-AUACAGCUAGAUAACCAAAGAUU-3’ | |
| miR-326 | Sense: 5’-CCUCUGGGCCCUUCCUCCAG-3’ |
| Antisense 5’-GGAGGAAGGGCCCAGAGGUU-3’ | |
| miRNAs Inhibitor | |
| NC | 5’-CAGUACUUUUGUGUAGUACAA-3’ |
| miR-9 | 5’-UCAUACAGCUAGAUAACCAAAGA-3’ |
| miR-326 | 5’-CUGGAGGAAGGGCCCAGAGG-3’ |
Abbreviations: DRD2, dopamine receptor D2; MUT, mutation; WT, wild-type.
*The reverse primers of miRNAs and U6 were included in the kit, but no sequence was provided.
Figure 1.Comparison of behavioral indices. (A-E) Comparison of ambulatory distance (A), the number of vertical movements (B), fecal pellets (C), sucrose preference of rate (D), and immobility time (E) among groups. * P< .05 vs NOR for saline treatment; Δ P < .05 vs CUS for saline treatment; ǂ P < .05 vs MD for saline treatment; & P < .05 between 2 treatments.
Figure 2.Dopamine receptor D2 (DRD2) protein and mRNA expression in the nucleus accumbens (NAc) and striatum. Comparison of DRD2 mRNA (A) and protein (B) expression in the NAc among groups. Comparison of DRD2 mRNA (C) and protein (D) expression in the striatum among groups. * P<.05 vs normal control (NOR) for saline treatment; Δ P<.05 vs chronic unpredictable stress (CUS) for saline treatment; ǂ P<.05 vs maternal deprivation (MD) for saline treatment. E, escitalopamine; S, saline.
Figure 3.Expression of miRNAs in the nucleus accumbens (NAc) and striatum. Comparison of miR-9 (A) and miR-326 (B) expression in the NAc among groups. Comparison of miR-9 (C) and miR-326 (D) expression in the striatum among groups. * P<.05 vs normal control (NOR) for saline treatment; Δ P<.05 vs chronic unpredictable stress (CUS) for saline treatment; ǂ P<.05 vs maternal deprivation (MD) for saline treatment. & P<.05 between 2 treatments.
Correlations between Behavioral Index and Gene Expression
| Ambulatory Distance | Vertical Counts | Fecal Pellets | Sucrose Preference Rate | Body Weight | Immobility Time | ||
|---|---|---|---|---|---|---|---|
| In the NAc | |||||||
| miR-9 | F(p) | 23.39 (.00) | 17.50 (.00) | 4.78 (.03) | 18.10 (.00) | 12.26 (.00) | 27.30 (.00) |
| R2 | 0.332 | 0.271 | .09 | 0.278 | 0.207 | 0.37 | |
| β(p) | 0.58 (.00) | 0.52 (.00) | -0.30 (.03) | 0.53 (.00) | 0.46 (.00) | -0.61 (.00) | |
| miR-326 | F(p) | 30.67 (.00) | 16.50 (.00) | 1.23 (0.27) | 8.11 (.01) | 3.00 (.09) | 14.49 (.00) |
| R2 | 0.395 | 0.260 | .026 | 0.147 | .060 | 0.236 | |
| β(p) | -0.63 (.00) | -0.51 (.00) | 0.16 (0.27) | -0.38 (.01) | -0.25 (.09) | 0.49 (.00) | |
| DRD2 mRNA | F(p) | 40.27 (.00) | 37.74 (.00) | 0.77 (0.39) | 14.76 (.00) | 5.50 (.02) | 33.28 (.00) |
| R2 | 0.461 | 0.432 | .016 | 0.239 | 0.105 | 0.415 | |
| β(p) | -0.68 (.00) | -0.66 (.00) | 0.13 (0.39) | -0.49 (.00) | -0.32 (.02) | 0.64 (.00) | |
| DRD2 Protein | F(p) | 21.11 (.00) | 31.70 (.00) | 5.41 (.02) | 40.99 (.00) | 12.58 (.00) | 37.66 (.00) |
| R2 | 0.310 | 0.403 | 0.103 | 0.466 | 0.211 | 0.445 | |
| β(p) | -0.56 (.00) | -0.64 (.00) | 0.32 (.02) | -0.68 (.00) | -0.46 (.00) | 0.67 (.00) | |
| In the striatum | |||||||
| miR-9 | F(p) | 0.26 (0.62) | 6.71 (.01) | 18.42 (.00) | 35.87 (.00) | 42.64 (.00) | 4.75 (.03) |
| R2 | .005 | 0.125 | 0.282 | 0.433 | 0.476 | .092 | |
| β(p) | .07 (0.62) | 0.35 (.01) | -0.53 (.00) | 0.66 (.00) | 0.69 (.00) | -0.30 (.03) | |
| miR-326 | F(p) | 29.14 (.00) | 32.59 (.00) | 2.65 (0.11) | 12.20 (.00) | 12.33 (.00) | 18.94 (.00) |
| R2 | 0.383 | 0.409 | .053 | 0.206 | 0.208 | 0.287 | |
| β(p) | 0.62 (.00) | 0.64 (.00) | -0.23 (0.11) | 0.45 (.00) | 0.46 (.00) | -0.54 (.00) | |
| DRD2 mRNA | F(p) | 0.55 (0.46) | 6.62 (.01) | 12.39(.00) | 13.00 (.00) | 24.21 (.00) | 2.91 (.01) |
| R2 | .011 | 0.123 | 0.209 | 0.217 | 0.34 | .058 | |
| β(p) | -0.11 (0.46) | -0.35 (.01) | 0.46 (.00) | -0.47 (.00) | -0.58 (.00) | 0.24 (.01) | |
| DRD2 Protein | F(p) | 13.68 (.00) | 25.52 (.00) | 2.38 (0.13) | 10.60 (.00) | 6.02 (.02) | 20.79 (.00) |
| R2 | 0.225 | 0.352 | .048 | 0.184 | 0.114 | 0.307 | |
| β(p) | -0.48 (.00) | -0.59 (.00) | 0.22 (0.13) | -0.43 (.00) | -0.34 (.02) | 0.55 (.00) | |
Abbreviations: NAc, nucleus accumbens.
Figure 4.microRNAs (miRNAs) regulated dopamine receptor D2 (DRD2) expression in vitro. (A) Nucleotide base of DRD2 mRNA 3’ untranslated region (3’-UTR) pairs with miR-9 and miR-326. (B) The expression of FAM (green) after transfection of miR-9 and miR-326 into SH-SY5Y cell. (C) The expression of miR-9 and miR-326 after transfection of mimics or inhibitor into SH-SY5Y cell. (D) The expression of DRD2 mRNA after transfection of mimics or inhibitor into SH-SY5Y cell. (E) Western blot of DRD2 and ß-actin after transfection of mimics and inhibitor into SH-SY5Y cell. (F) Relative luciferase activity of DRD2 (wild-type, WT) 3’UTR and its mutation (MUT) reporter after cotransfection of plasmid and miR-9 mimics (or negative control mimics) into 293T cell. *P < .05.